PubMed Health⌕ Search

PubMed · 16290349

Settling and deformation of a thin elastic shell on a thin fluid layer lying on a solid surface.

Abstract

placement of a soft contact lens onto the cornea, the upper eyelid deforms and settles the lens by squeezing fluid out of the post-lens tear film or POLTF (i.e., the tear fluid layer sandwiched between the lens and the cornea). This paper studies the physical mechanisms that control the dynamic state of the contact lens during blinking, i.e., its shape and its distance from the cornea, especially a long time after insertion. We model the lens as a deformable elastic shell and the cornea as a flat nondeformable body. The tear fluid is assumed to be Newtonian, and the lens is characterized by an elastic modulus and a Poisson ratio. Lubrication equations under creeping flow are used to solve the fluid problem, while the thin-shell approximation is applied to the solid lens. The solid and fluid mechanics problems are coupled by maintaining continuity of stress and velocity at the solid/liquid interface. Lid applied pressure causes the lens to approach the cornea by squeezing tear fluid out and also leads to the deformation of the lens. Subsequently, in the interblink period, since there is no applied force, the elastic energy stored in the lens due to its deformation is released causing it to move away from the cornea by imbibing tear fluid into the POLTF. If the POLTF thickness is large, the inward motion of the lens in the blink is more than the outward motion during interblink, and this causes the lens to settle closer to the cornea. Eventually, there may be a balance of the inward motion during the blink and the outward motion during the interblink. If so, the lens subsequently exhibits periodic steady-state motion. However, it is also possible that a balance of inward and outward motion is never achieved, and the lens continues to settle endlessly. If this happens, then the thinfilm interactions between the mucin-covered corneal surface and the lens material determine whether the lens actually touches the cornea and possibly adheres. Our elastohydrodynamic analysis serves as a useful tool to elucidate the effects of various lens parameters on the final settled state of the lens. In particular, we are concerned about eventual adherence and/or mechanical abrasion to the cornea, which is very important to the ocular health of soft contact lens wearers.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Chauhan, C J Radke. 2002-01-01. Settling and deformation of a thin elastic shell on a thin fluid layer lying on a solid surface.. https://doi.org/10.1006/jcis.2001.8008

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗